| Name | Title | Contact Details |
|---|
Spirovant is a gene therapy company focused on changing the course of cystic fibrosis and other respiratory diseases. The company`s current investigational gene therapy technologies are designed to overcome the historical barriers that have prevented effective genetic treatments for cystic fibrosis. Spirovant`s lead programs are in development for cystic fibrosis. Spirovant is a wholly owned subsidiary of Sumitovant Biopharma Ltd., which is itself a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. Spirovant is located in Philadelphia, PA.
Pioneering the next generation of non-viral gene therapy - by tackling more diseases, more precisely and in a more personalized way.
Q-Chuck Technologies Inc. is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.
Avellino is a global leader in precision medicine, focused on innovative genetic diagnostics, gene therapies, and genetic data for modern eyecare practices.